Safety and Pharmacokinetics of Olamkicept Doses up to 2400 mg in Healthy Japanese Men: Phase I, Randomized, Placebo‐Controlled, and Double‐Blind Trial
Clinical and Translational Science · 2026-08 · 19 (8)
DOI: 10.1111/cts.70673 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Translational Science, online erschienen am 26.07.2026. Verfasst von Ryuzo Hanada und 7 weiteren Autor:innen. Beteiligte Einrichtung: SOUSEIKAI Sumida Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Recombinant Fusion Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ferring Pharmaceuticals, Ferring Pharmaceuticals Netherlands.
Abstract (Originalsprache)
The first‐in‐class, fully human fusion protein, olamkicept, selectively inhibits trans interleukin‐6 signaling. Previously, the safety, tolerability, pharmacokinetics (PK), and immunogenicity of olamkicept following single ascending doses (SAD) up to 750 mg and multiple ascending doses (MAD) up to 600 mg daily were assessed. To assess higher doses, parallel trials of olamkicept up to 2400 mg daily were separately performed in healthy European and Japanese adult men. In this phase I, single‐center, within‐group randomized, double‐blind trial, Japanese participants were randomized to SAD olamkicept infusions (1200, 1800, and 2400 mg) or placebo. The primary objective was to assess the safety of higher doses of olamkicept based on treatment‐emergent adverse events (TEAEs), vital signs, electrocardiograms (ECG), and clinical chemistry. PK parameters were included as secondary outcomes. Immunogenicity was not assessed in the present Japanese cohort. Twenty‐four participants were randomized. Four TEAEs and no adverse drug reactions were reported. All TEAEs were mild and resolved without intervention. There were no treatment or dose related trends in TEAEs, vital signs, ECG, clinical chemistry, hematology, hemostasis, or urinalysis. A single infusion of olamkicept achieved measurable serum concentrations for up to 28 days after treatment and exposure was dose proportional. In conclusion, single doses of olamkicept up to 2400 mg have a favorable safety profile and dose proportional PK in healthy Japanese men. Trial Registration: ClinicalTrials.gov identifier: NCT06515834
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- SOUSEIKAI Sumida Hospital, Tokyo, Japan.
- Ferring Pharmaceuticals, International PharmaScience Center, Kastrup, Denmark.
- Ferring Pharmaceuticals Co. Ltd., Tokyo, Japan.
ORCID-Profile: Katharina Bruzelius, Arjun Ravi, Philippe Pinton
Förderung
- Ferring Pharmaceuticals
- Ferring Pharmaceuticals Netherlands
Zitieren
APA
Hanada, R., Bruzelius, K., Falkenberg, M., Kyhl, L. E., Møgelmose, S., Ravi, A., Pinton, P., & Yoneshima, N. (2026). Safety and Pharmacokinetics of Olamkicept Doses up to 2400 mg in Healthy Japanese Men: Phase I, Randomized, Placebo‐Controlled, and Double‐Blind Trial. Clinical and Translational Science, 19(8). https://doi.org/10.1111/cts.70673
Vancouver
Hanada R, Bruzelius K, Falkenberg M, Kyhl LE, Møgelmose S, Ravi A, et al. Safety and Pharmacokinetics of Olamkicept Doses up to 2400 mg in Healthy Japanese Men: Phase I, Randomized, Placebo‐Controlled, and Double‐Blind Trial. Clinical and Translational Science. 2026;19(8). doi:10.1111/cts.70673
BibTeX
@article{Hanada2026,
author = {Hanada, Ryuzo and Bruzelius, Katharina and Falkenberg, Michael and Kyhl, Lars-Erik and Møgelmose, Signe and Ravi, Arjun and Pinton, Philippe and Yoneshima, Naomichi},
title = {Safety and Pharmacokinetics of Olamkicept Doses up to 2400 mg in Healthy Japanese Men: Phase I, Randomized, Placebo‐Controlled, and Double‐Blind Trial},
journal = {Clinical and Translational Science},
year = {2026},
volume = {19},
number = {8},
doi = {10.1111/cts.70673}
}
EUVIMED